•
Sep 30, 2024

Glaukos Q3 2024 Earnings Report

Glaukos' third quarter results for 2024 reflected strong performance with record net sales and successful execution of strategic plans.

Key Takeaways

Glaukos Corporation reported record net sales of $96.7 million for the third quarter of 2024, a 24% increase year-over-year. The company's glaucoma sales reached $76.0 million, up 30% year-over-year, while corneal health sales increased by 5% to $20.6 million. The company raised its 2024 net sales guidance to $377 million to $379 million.

Record net sales of $96.7 million, a 24% increase year-over-year.

Glaucoma net sales reached a record $76.0 million, up 30% year-over-year.

Corneal Health net sales increased by 5% year-over-year to $20.6 million.

2024 net sales guidance raised to $377 million - $379 million.

Total Revenue
$96.7M
Previous year: $78M
+23.9%
EPS
-$0.28
Previous year: -$0.5
-44.0%
Gross margin
77%
Previous year: 76%
+1.3%
Non-GAAP gross margin
82%
Previous year: 83%
-1.2%
SG&A expenses
$64M
Previous year: $54.2M
+18.0%
Gross Profit
$74.1M
Previous year: $59.5M
+24.4%
Cash and Equivalents
$100M
Previous year: $109M
-8.1%
Free Cash Flow
-$11M
Previous year: -$11.5M
-4.3%
Total Assets
$927M
Previous year: $949M
-2.3%

Glaukos

Glaukos

Glaukos Revenue by Segment

Forward Guidance

The company expects 2024 net sales to be in the range of $377 million to $379 million based on the latest foreign currency exchange rates.

Revenue & Expenses

Visualization of income flow from segment revenue to net income